Related Experiment Video
Updated: May 5, 2026

Isolation of Soluble and Insoluble PrP Oligomers in the Normal Human Brain
Published on: October 3, 2012
Beyond PrP res type 1/type 2 dichotomy in Creutzfeldt-Jakob disease
Emmanuelle Uro-Coste1, Hervé Cassard, Stéphanie Simon
1INSERM U858, Institut de Médecine Moléculaire de Rangueil and Service d'Anatomie Pathologique et Histologie-Cytologie, C.H.U. Rangueil, Toulouse, France.
Abstract:
Sporadic Creutzfeldt-Jakob disease (sCJD) cases are currently subclassified according to the methionine/valine polymorphism at codon 129 of the PRNP gene and the proteinase K (PK) digested abnormal prion protein (PrPres)identified on Western blotting (type 1 or type 2). These biochemically distinct PrPres types have been considered to represent potential distinct prion strains. However, since cases of CJD show co-occurrence of type 1 and type 2 PrPres in the brain, the basis of this classification system and its relationship to agent strain are under discussion. Different brain are as from 41 sCJD and 12 iatrogenic CJD (iCJD) cases were investigated, using Western blotting for PrPres and two other biochemical assays reflecting the behaviour of the disease-associated form of the prion protein (PrPSc) under variable PK digestion conditions. In 30% of cases, both type 1 and type 2 PrPres were identified. Despite this, the other two biochemical assays found that PrPSc from an individual patient demonstrated uniform biochemical properties. Moreover, in sCJD, four distinct biochemical PrPSc subgroups were identified that correlated with the current sCJD clinico-pathological classification. In iCJD, four similar biochemical clusters were observed, but these did not correlate to any particular PRNP 129 polymorphism or western blot PrPres pattern. The identification of four different PrPSc biochemical subgroups in sCJD and iCJD, irrespective of the PRNP polymorphism at codon 129 and the PrPres isoform provides an alternative biochemical definition of PrPSc diversity and new insight in the perception of Human TSE agents variability.
Insights
This study re-evaluates prion protein classification in Creutzfeldt-Jakob disease (CJD). New biochemical subgroups of abnormal prion protein (PrPSc) offer a refined understanding of human prion diseases and their variability.
Area of Science:
- Neuroscience
- Biochemistry
- Prion Diseases
Background:
- Sporadic Creutzfeldt-Jakob disease (sCJD) classification relies on PRNP codon 129 genotype and PrPres type (1 or 2).
- The coexistence of PrPres types in CJD cases challenges the current classification and its link to distinct prion strains.
- Understanding prion protein (PrPSc) diversity is crucial for human transmissible spongiform encephalopathies (TSEs).
Purpose of the Study:
- To investigate the biochemical properties of abnormal prion protein (PrPSc) in sporadic and iatrogenic CJD.
- To explore an alternative biochemical classification of PrPSc diversity.
- To gain new insights into the variability of human TSE agents.
Main Methods:
- Analysis of brain tissue from 41 sCJD and 12 iatrogenic CJD (iCJD) cases.
- Western blotting for proteinase K (PK)-resistant prion protein (PrPres).
- Two additional biochemical assays assessing PrPSc behavior under variable PK digestion.
Main Results:
- Both PrPres type 1 and type 2 were found in 30% of cases, yet PrPSc exhibited uniform biochemical properties within individual patients.
- Four distinct biochemical PrPSc subgroups were identified in sCJD, correlating with clinico-pathological classifications.
- Four similar biochemical clusters were observed in iCJD, independent of PRNP codon 129 polymorphism or PrPres type.
Conclusions:
- The study proposes four distinct PrPSc biochemical subgroups as an alternative definition for PrPSc diversity in CJD.
- These findings offer new perspectives on the variability of human TSE agents.
- Biochemical PrPSc profiling provides a more nuanced classification beyond PRNP genotype and PrPres isoforms.
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Type I Diabetes II: Pathophysiology
Encephalitis ll: Pathophysiology
Alzheimer Disease ll: Pathophysiology
Parkinson Disease ll: Pathophysiology
Huntington Disease l: Introduction

